Prototype Drugs KEY NOTES only (week 11)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/9

encourage image

There's no tags or description

Looks like no tags are added yet.

10 Terms

1
New cards

Aspirin

Pharm Class: Salicylate/NSAIDs

Therapeutic class: Anti-inflammatory, Antipyretic, Analgesic, Anti-platelet

Precautions:

-Stop at least 1 week prior to surgery, if possible

-Avoid use in children w/ viral illnesses

-Contraindicated w/ active bleeding

Pharmacokinetics:

-Oral: 5-30 min onset; D: 3-6 hr

-Rectal: 1-2 hr onset; D:6-8 hr

AE: n/v, heartburn, epigastric discomfort, occult blood loss, dizziness, tinnitus, acidosis, salicylism toxicity; Reye's syndrome (in children and adolescents)

Interactions: anticoagulants, increased risk of hypoglycemia with oral hypoglycemic agents

Teach patients to report:

-Buzzing in ears, ringing (ototoxicity)



2
New cards

Ibuprofen

Pharm Class: Propionic acid/NSAID

Therapeutic Class: NSAID, Antipyretic, Analgesic

Indication: relief of s/s of rheumatoid arthritis and

OA; relief of mild-mod pain; dysmenorrhea; fever

Action: inhibits prostaglandin synthesis by

block COX 1 and COX 2 receptor sites

AE: h/a, dizziness, somnolence, fatigue, rash, nausea, dyspepsia, bleeding, constipation, bone marrow suppression, MI, stroke

Interactions:

-decreased effect w/loop diuretics

-decreased effect of beta blockers

-Increase lithium toxicity

-increase risk of bleeding w/ anticoagulants, alcohol, glucocorticoids

3
New cards

celecoxib

Pharm Class: Selective COX 2 Inhibitor/NSAID

Therapeutic Class: 2nd generation NSAID for mild to moderate pain

Indication: Last choice med for chronic pain. Arthritis, dysmenorrhea, ST pain

Action: decreases inflammation, fever, and pain by inhibiting COX 2

AE: MI, CVA, h/a, dizziness, sinusitis, nausea, flatulence, diarrhea, rash, peripheral edema

Administration Guidelines: encourage client to take w/ food

Teach risk of MI and stroke d/t suppression of vasodilation

Contraindications: Allergy to sulfonamides

Interactions:

-decreased effect of ACE inhibitors

-Increased INR w/ warfarin

-Increased toxicity of lithium and fluconazole

4
New cards

acetaminophen (Tylenol)

Pharm Class: Centrally Acting Cox Inhibitor

Therapeutic Class: Antipyretic & Analgesic

Action: Acts directly on the hypothalamus to cause vasodilation and sweating, which will reduce fever; MOA of analgesic is not understood

Indications: mild to moderate pain and fever

Pharmacokinetics:

-Oral: onset varies; D:3-6 hr

-IV: onset is immediate; D:4-6 hr

AE: rash, fever, chest pain, liver toxicity and failure, myelosuppression

Interactions:

-increased risk of bleeding d/t liver toxicity

-increased risk of hepatoxicity w/ cirrhosis, ETOH use, barbiturates, carbamazepine, hydantoins, or rifampin

5
New cards

interferon alfa-2B

Pharm Class: Interferon

Therapeutic Class: Immunostimulant

*Prepared by recombinant DNA technology

Indication: hairy cell leukemia, malignant

melanoma, advanced HIV r/t Kaposi sarcoma, chronic Hep B & C, follicular lymphoma

Action: Inhibits growth of tumor cells and enhances

immune response

AE: dizziness, confusion, rash, dry skin, anorexia, nausea, bone marrow suppression, flulike syndrome (fever, chills, fatigue)

Administration Guidelines: Available for IV, IM, and SQ administration

*Prolonged therapy can lead to serous toxicity:

immunosuppression/myelosuppression, hepatotoxicity, neurotoxicity

Interactions: Increased risk of theophylline toxicity

Nursing considerations:

-Teach pt to report fever, malaise, weakness, vaginal yeast infections, gingivitis, and increased bleeding

-Teach pt to report s/s of neurotoxicity, myelosuppression, hepatotoxicity

-Teach pt to rise slowly

6
New cards

aldesleukin

Pharm Class: Interleukin

Therapeutic Class: Immune stimulant

Indication: metastatic renal cell carcinoma in adults; metastatic melanomas

Action: activates human cellular immunity and inhibits tumor growth through increase in lymphocytes, platelets, and cytokines

AE: mental status changes, dizziness, hypotension, sinus tachycardia, arrhythmias, pruritus, n/v, diarrhea, anorexia, GI bleed, bone marrow suppression, respiratory difficulties, fever, chills, pain

Interactions: avoid other cardio or neurotoxic meds-mat exacerbate adverse effects

7
New cards

filgrastim

Pharm Class: CSF

Therapeutic Class: Immune stimulant

Indication: reduction of incidence of infection and time to neutrophil recovery w/myelosuppressive chemotherapy, leukemia, and bone marrow transplants

Action: increased production of neutrophils in bone marrow

AE: h/a, fatigue, alopecia, rash, n/v, diarrhea, stomatitis, anorexia, bone pain, cough, generalized pain

Administration Guidelines:

-Monitor CBC

-Given IV or SQ

8
New cards

cyclosporine

Pharm Class: T and B cell suppressor

Therapeutic Class: immunosuppressant

Indication: prophylaxis for organ rejection in kidney, liver, and heart transplants; RA; Psoriasis

Action: reversibly inhibits immunocompetent lymphocytes; inhibits T helper cells and T suppressor cells, lymphokine production, and release of IL2 and T cell growth factor

AE: tremor, HTN, gingival hyperplasia, renal dysfunction, diarrhea, hirsutism, acne, bone marrow suppression

*AVOID PREGNANCY until at least 4 months after completion

Interactions: avoid other nephro and hepatotoxic agents

*AVOID GRAPEFRUIT JUICE (increases cyclosporine levels)

9
New cards

pembrolizumab

Pharm Class: Monoclonal Antibody

Therapeutic Class: Immunosuppressant

Indications: treatment of cancers: breast, biliary tract, cervical, cutaneous squamous cell, endometrial, esophageal, gastric, head/neck, liver, Merkel cell, lung, kidney; melanoma, Hodgkin lymphoma

Action: inhibits programmed cell death-1 activity from binding to T cells; allows T cells to be more active

AE: cardiovascular toxicity (MI, myocarditis, pericarditis, arrhythmias), rash (severity rangescan be fatal), endocrine alterations, GI variations, liver impairment, GBS, periph. neuropathy, meningitis, ophthalmic toxicity, pulm. toxicity, edema

Interactions: Severe immune suppression can occur if combined with another immunosuppressant agent

10
New cards

omalizumab

Pharm Class: Immune Modulator

Therapeutic Class: Immunosuppressant

Indication: moderate to severe asthma in adults and pediatric patients >6 y.o. w/positive skin test to a perennial aeroallergen (symptoms inadequately controlled by inhaled corticosteroids)

Action: antibody that binds to IgE receptors on mast cells, basophils, and dendritic cells; decreases IgE mediated inflammation

AE: arthralgia, myalgia, fatigue, dizziness, rash, h/a, URI, injection site reactions, anaphylaxis, hypersensitivities

Administration Guidelines: Not for acute attack

SQ every 2-4 weeks